Mycoplasma Testing Market Size, Share, Industry Analysis, and Growth Forecast

The Mycoplasma Testing Market is undergoing a significant technological transformation as laboratories and biopharmaceutical manufacturers move toward faster and more efficient contamination detection methods. Traditional culture-based testing remains important, but molecular technologies are increasingly being adopted because they can shorten testing timelines and support faster decision-making.

Market Research Future estimates that the global market will increase from USD 1.21 billion in 2025 to USD 3.52 billion by 2035, reflecting a 10.20% CAGR during 2026–2035. One of the major factors behind this growth is the increasing emphasis on quality assurance in biopharmaceutical manufacturing.

PCR-based testing has gained substantial attention because of its sensitivity and rapid turnaround capabilities. Modern molecular assays can identify mycoplasma contamination considerably faster than traditional methods, making them useful for research laboratories, pharmaceutical companies, biotechnology firms, and contract testing organizations. Industry developments are also supporting the movement toward automated sample-to-answer workflows.

The growth of biologics and advanced therapies is another important factor. Cell and gene therapies rely heavily on cell-based manufacturing processes, where contamination can compromise research outcomes and product quality. Consequently, manufacturers increasingly require testing at several stages of production. Market Research Future identifies cell and gene therapy pipeline expansion as a key trend influencing testing demand.

Regulatory requirements further strengthen demand. Pharmaceutical and biotechnology organizations must demonstrate appropriate quality controls to ensure biological products meet safety and manufacturing standards. As regulatory scrutiny increases, mycoplasma testing becomes an essential component of contamination-control strategies rather than an optional laboratory procedure.

North America remains a leading market because of its large biopharmaceutical manufacturing base and established research infrastructure. Meanwhile, Asia-Pacific offers substantial opportunities due to expanding biomanufacturing facilities and increasing laboratory capabilities.

Going forward, rapid PCR, digital PCR, automated testing systems, and integrated laboratory platforms are expected to influence market development. These technologies can help manufacturers improve testing efficiency, minimize production delays, and strengthen contamination monitoring.